Nectar Lifesciences Addresses EU Regulatory Observations

Nectar Lifesciences' API manufacturing facility in Punjab received seven EU regulatory observations, including four critical ones, following a joint inspection by EDQM and AEMPS. The company is addressing these concerns through a Corrective Action and Preventive Action (CAPA) plan to ensure compliance with EuGMP standards. A re-inspection will verify the corrective measures, determining the facility's EuGMP approval. Shares of Nectar Lifesciences fell 5% on the BSE due to the news. The company remains committed to maintaining quality standards and compliance.

 

Sources: NSE, BSE, Reuters, Business Standard